Cardiff Lexingto Stock Price, News & Analysis

Cardiff Lexington Corporation (OTC PINK:CDIX) reported its 3rd quarter financial results for the period ending September 30, 2022. Key highlights include:

• Stockholders' Equity: Increased by 131%, totaling $6.4 million.
• Total Assets: Rose by 43%, reaching $15.9 million.
• Revenue: Grew by 47%, amounting to $9.4 million.
• Gross Margin: Up by 43%, totaling $6 million.
• Net Loss: Decreased by $1.9 million to ($813,054).

Management expressed optimism about moving beyond cash flow survival.

Cardiff Lexington Corporation (OTC PINK:CDIX) reported remarkable financial results for the 2nd quarter ended June 30, 2022. The company achieved a 95% increase in revenue to $6.07 million, compared to $3.11 million for the same period in 2021. Their gross margin also rose by 92% to $3.82 million. Notably, net income reached $61,826, a $3.1 million improvement from last year, while net loss decreased by $4.33 million. CEO Alex Cunningham expressed optimism for continued growth, anticipating strong results for the impending third quarter.

Cardiff Lexington Corporation (OTC PINK:CDIX) reported a significant turnaround in its financial results for the year ended December 31, 2021. Total stockholders' equity soared to $2.78 million from ($8.87 million) in 2020, marking an increase of $11.65 million. Total assets rose by 126% to $11.16 million, while total liabilities dropped by 40% to $8.38 million. Revenue surged 190% to $10.01 million, and gross margin improved 245% to $6.16 million. Although there was a net loss of ($409,707), this represented an 85% decrease in losses compared to the previous year.

Cardiff Lexington Corporation (OTC PINK:CDIX) released its pro forma historical profit and loss statement, incorporating its recent acquisition of Nova Ortho and Spine. The acquisition is expected to drive growth as Cardiff Lexington's Healthcare Division adds resources for revenue generation. In 2020, combined revenue reached $7.6 million, up 43% from 2019. Notably, net cash improved by over $1 million, and stockholders' equity increased by $7.2 million. The company's focus remains on a 'Buy and Build' strategy within healthcare and financial services.

Cardiff Lexington Corporation (OTC PINK:CDIX) has acquired Nova Ortho and Spine, LLC, marking the launch of its Healthcare Division. The acquisition, valued at $6,079,334, includes cash and stock components, with a potential performance-based supplement in 2022. Nova Ortho will expand Cardiff's reach in Florida, focusing on integrating complementary healthcare services. With a management team experienced in optimizing growth, the subsidiary expects a 30% internal growth rate as Cardiff Lexington aims to build a robust holding company in niche healthcare markets.

Cardiff Lexington Corporation (CDIX) recently reported its financial results for Q1 2021, revealing a net loss of $1,574,267, a 72% improvement from the previous year's loss of $5,575,757. The loss per share decreased by over 89%, amounting to (5.33), compared to (48.93) in Q1 2020. Notably, the company reported a net positive change of $3,977,394 year-over-year. Additionally, cash and cash equivalents rose to $510,760 from $99,860, highlighting improved liquidity. Cardiff Lexington's management aims to reduce convertible debt and enhance its acquisition strategy in healthcare and financial services.

Cardiff Lexington Corporation (OTC PINK:CDIX) reported its financial results for the year ending December 31, 2020. The company experienced a significant reduction in net loss, decreasing from $6.3 million in 2019 to $2.4 million in 2020, despite challenges posed by the Covid-19 pandemic. Revenue was 93% of 2019 levels. The fair value of derivative liabilities decreased by 22.5%. The company is focusing on future acquisitions in the financial services and healthcare sectors, undergoing due diligence including audits. Management anticipates measurable impacts in 2021.